Abstract
Background Conventional manual surveillance of healthcare-associated infections is labour-intensive and therefore often restricted to areas with high-risk patients. Fully automated surveillance of hospital-onset bacteraemia and fungaemia (HOB) may facilitate hospital-wide surveillance.
Aim To develop an algorithm and minimal dataset (MDS) required for automated surveillance of HOB and apply it to real-life routine data in four European hospitals.
Methods Through consensus discussion a HOB definition with MDS suitable for automated surveillance was developed and applied in a retrospective multicentre observational study including all admitted adult patients (2018-2022). HOB was defined as a positive blood culture with a recognised pathogen two or more days after hospital admission. For common commensals, two blood cultures with the same commensal within two days were required. Annual HOB rates were calculated per 1,000 patient days for the hospital and for intensive care units (ICU) and non-ICU.
Results HOB rates were comparable between the four hospitals (1.0 to 2.2 per 1,000 patient days). HOB rates were substantially higher in ICU than non-ICU across the four hospitals, and HOB with common commensals accounted for 14.8-28.2% of all HOB. HOB rates per 1,000 patient days were rather consistent over time, but were higher in 2020 and 2021. HOB caused by Staphylococcus aureus accounted for 8.4-16.0% of all HOB.
Conclusion Automated HOB surveillance using a common definition was feasible and reproducible across four European hospitals. Future studies should investigate clinical relevance and preventability of HOB, and focus on strategies to make the automated HOB metric an actionable infection control tool.
Competing Interest Statement
SvdW and PN are involved in the company P3S (Patient Safety Surveillance Solutions) that works on automated surveillance for adverse events. NB received a Mobility grant from the Swiss National Science Foundation (Grant number: P400PM_183865) in 2021. The other authors declare that they have no competing interests.
Funding Statement
The work at UMC Utrecht was funded by the RZN ABR network Utrecht through a grant from the Dutch Ministry of Healthcare, Welfare and Sport (grant number 331724). Activities concerning hospital-onset bacteraemia and fungaemia at Charité-Universitätsmedizin Berlin are partially funded within the project RISK PRINCIPE, which is supported by the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung (DLR Projektträger)), Germany (grant number: 01ZZ2323E). The work in Stockholm was supported by Sweden's Innovation Agency (Vinnova grant 2018-03350) and Swedish Research Council (VR grant 2021-02271). PN was supported by Region Stockholm (clinical research appointment; ALF grant 2019-1054).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In all hospitals ethical approval was obtained separately and informed consent was not needed; if applicable per local regulations patients who objected to the use of their data for the purpose of research were excluded. Process numbers of ethical approval are as follows: UMC Utrecht: 21-856DB; Charité-Universitätsmedizin Berlin: EA2/060/23; Region Stockholm: 2018/1030-31. The data collection and analysis of the Swiss cohort at Hôpitaux universitaires de Genève (HUG) was considered as falling outside of the scope of the Swiss legislation regulating research on human subjects, so that the need for local ethics committee approval was waived by the Commission Cantonale d'éthique de la Rercherche de Genève (decision number: Req-2024-01048).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵p The members of the network are listed under Collaborators
Data availability
The datasets generated and/or analysed during the current study are not publicly available due to ethical limitations related to sharing patient information, but are available via the corresponding author on reasonable request.
